The Syros Pharmaceuticals, Inc. (SYRS) Receives Average Recommendation of “Buy” from Brokerages

The Syros Pharmaceuticals, Inc. (SYRS) Receives Average Recommendation of “Buy” from Brokerages

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) have earned an average recommendation of “Buy” from the nine brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $24.47.

A number of research analysts recently weighed in on SYRS shares. JMP Securities upgraded shares of Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 target price on the stock in a research note on Thursday, September 28th. ValuEngine upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Cann restated a “buy” rating and set a $28.00 target price on shares of Syros Pharmaceuticals in a research note on Monday, August 21st. Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Finally, Roth Capital started coverage on shares of Syros Pharmaceuticals in a research note on Monday. They set a “neutral” rating and a $15.00 target price on the stock.

Syros Pharmaceuticals (NASDAQ:SYRS) traded down 1.49% during midday trading on Wednesday, hitting $16.50. The company’s stock had a trading volume of 155,227 shares. Syros Pharmaceuticals has a 12 month low of $10.22 and a 12 month high of $24.38. The company’s 50 day moving average price is $16.13 and its 200 day moving average price is $16.13. The firm’s market cap is $433.29 million.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Wednesday, August 9th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.03. Analysts expect that Syros Pharmaceuticals will post ($2.09) EPS for the current year.

In other Syros Pharmaceuticals news, insider Eric R. Olson sold 2,500 shares of the business’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $23.59, for a total value of $58,975.00. Following the sale, the insider now owns 2,500 shares in the company, valued at approximately $58,975. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Richard A. Young sold 3,282 shares of the business’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $22.00, for a total transaction of $72,204.00. Following the completion of the sale, the director now owns 420,101 shares in the company, valued at approximately $9,242,222. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,332 shares of company stock worth $140,012. Corporate insiders own 33.60% of the company’s stock.

A number of hedge funds have recently made changes to their positions in SYRS. FMR LLC lifted its stake in Syros Pharmaceuticals by 11.9% in the 2nd quarter. FMR LLC now owns 3,926,998 shares of the company’s stock worth $63,185,000 after purchasing an additional 418,061 shares in the last quarter. Vanguard Group Inc. lifted its stake in Syros Pharmaceuticals by 189.6% in the 2nd quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock worth $6,156,000 after purchasing an additional 250,507 shares in the last quarter. State Street Corp lifted its stake in Syros Pharmaceuticals by 176.7% in the 2nd quarter. State Street Corp now owns 169,497 shares of the company’s stock worth $2,728,000 after purchasing an additional 108,250 shares in the last quarter. AWM Investment Company Inc. lifted its stake in Syros Pharmaceuticals by 155.8% in the 2nd quarter. AWM Investment Company Inc. now owns 121,624 shares of the company’s stock worth $1,957,000 after purchasing an additional 74,074 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its stake in Syros Pharmaceuticals by 646.3% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 34,390 shares of the company’s stock worth $553,000 after purchasing an additional 29,782 shares in the last quarter. Institutional investors and hedge funds own 59.69% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Related posts

Leave a Comment